Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
|Articles|March 1, 2009
- Applied Clinical Trials-03-01-2009
- Volume 0
- Issue 0
eClinical Software: March 2009
Author(s)Lisa Henderson
The latest eclinical software in the clinical trials industry.
Advertisement
Paper Submissions Support Added
Electronic/paper/hybrid modes addressed in new product suite
TAKE Solutions (Raleigh, NC) has added a Paper Submissions Module to its PharmaReady suite of Document & Submission Management products. The new module allows users of hybrid submission modes of electronic and paper to take advantage of an interim solution. The Paper Publishing Module is part of a centralized document management system.
TAKE updated PharmaReady suite
Key features of the system include: Assemble and organize documents based on volumes, modules, and agency-specific classifications; acceptance of all common Microsoft Office and PDF documents; various submission dossiers; agency-specific submission structures; create volume and module headers and separators; review print ready documents; and more.
TAKE Solutions, (609) 720-1002,
Advanced Clinical Trial Operations Planning
New portfolio or program level execution available
ClearTrial (Westmont, IL) has added an advanced planning feature to its Enterprise Edition of Clinical Version 2.7 clinical trial operations planning software. The feature, called ClearTrial Portfolio Planning, allows biopharmaceutical companies and CROs to roll-up protocol-level study plans into portfolio-level forecasts within mintues. This capability provides instant visibility to monthly budgets, monthly resource demand, and timelines across a program, business unit, therapeutic indication, region, service provider, or any other dimension. When protocol-level assumptions change, the software automatically updates the portfolio-forecast within seconds.
ClearTrial Portfolio Planning
ClearTrial Portfolio Planning is designed primarily for professionals in clinical operations, finance, and project/resource management.
ClearTrial, (630) 986-9800,
Platform Supports Processes
Subsequent modules will address eCTD- and CDISC-related activities
Octagon Research Solutions (Wayne, PA) announced its ViewPoint Quantum platform that supports the optional business modules and is the foundation for the ViewPoint Quantum environment for Business Process Management.
Octagon ViewPoint Quantum platform
These capabilities include workflow, issue management, search, metadata, document storage, and integrated connectivity with other content repositories.
It also ensures common function across business modules, which feature dynamic reporting capabilities, issue management capabilities, and workflows. Subsequent business modules include: eCTD, CDISC, and activities relating to these standards, which include global submission publishing, compilation, and lifecycle management.
Octagon Research Solutions, (610) 535-6500,
Articles in this issue
over 17 years ago
Putting a Face on EDCover 17 years ago
Patient Powerover 17 years ago
Transparency Shapes Pharmaceutical R&Dover 17 years ago
Poll Finds Ironic Inefficiencyover 17 years ago
Closer to Transparencyover 17 years ago
Is Clinical Research Recession Proof?over 17 years ago
Managing Content in 2009over 17 years ago
Eliminate the Disconnect in a Systems Approachover 17 years ago
What I Learned as a Subjectover 17 years ago
Risk Response: Constructing a PlanAdvertisement
Related to this article
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Clinical Trials Do Not Have a Data Problem, They Have a Decision-Readiness Problem
2
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
3
ACT Brief: Orchestrated AI Clinical Environments, eSource Coordinator Satisfaction, and Faster Clinical Trials Act
4
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
5